⌕
Kazia Therapeutics · KZIA · Nasdaq
Tenet 50 · Mixed
Compare
$5.37−2.19%At closeTenet 50 · Mixed
$5.37−0.12 (−2.19%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Kazia Therapeutics (KZIA) Stock

Kazia Therapeutics (KZIA) closed at $5.37 on Nov 19, 2026; its Tenet Score is 50 of 100 against 486 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Close
$5.37
Nov 19, 2026
Market cap
$68.2Munverified basis
share basis not confirmed
Dividend yield
57.70%
past year's regular dividends ÷ price
52-week range
4.86 – 17.40
low → high
Tenet Score
50/100
Mixed · 486 Healthcare peers

Industry: Drugs · see every company filed here →

Kazia Therapeutics Limited scores 50/100. Mixed. Strongest on growth, quality is the soft spot versus 486 Healthcare peers. Insufficient inputs: Tenet 50 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=486
50/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
17
Health
34
Growth
99

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value omitted — no data yet.
Value—QualityFHealthDGrowthA+MomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Withheld: the share basis behind this valuation is not verified.
P/B
—
Withheld: the share basis behind this valuation is not verified.
P/S
—
no P/S on file
ROE
−282%
fiscal 2026
Operating margin
−3618.7%
before interest and tax
Net margin
—
Not reported in the company's filings for this period.
Current ratio
2.33
fiscal 2026
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).

The whole report, at a glance · every card is a live peek, click any to open the section

About Kazia Therapeutics Limited

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential thera…

Composite computed Nov 20, 2026 · peer basis: Healthcare (n=486) · every glimpse links to its full section with sources · not investment advice.

What sector and industry is Kazia Therapeutics in?

Kazia Therapeutics is in the Healthcare sector and the Drugs industry.

What is Kazia Therapeutics' Tenet Score?

Kazia Therapeutics' Tenet Score is 50 out of 100, ranked against 486 Healthcare peers as of Nov 20, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.